Urgent

Multiple sclerosis — acute relapse & disease-modifying therapy (MS, RRMS, clinically isolated syndrome)

CNS demyelination · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Immune-mediated CNS demyelination; relapsing-remitting (RRMS) most common. Acute relapse = new/worsening neurological symptoms lasting >24h, >=30 days from last relapse, not explained by infection/fever (pseudorelapse/Uhthoff). ED role: confirm relapse vs pseudorelapse/mimic, exclude infection, treat disabling relapse with steroids, and refer for disease-modifying therapy (DMT).

Red flags

  • Rapidly progressive weakness / respiratory involvement — consider NMOSD, high cervical cord, transverse myelitis
  • Bilateral or severe optic neuritis, intractable vomiting/hiccups, area postrema syndrome — suggests NMOSD (do not delay AQP4 testing; steroids +/- PLEX)
  • Fever + neurological decline — exclude infection before steroids
  • New bladder/bowel dysfunction + saddle anaesthesia — cord lesion, urgent MRI
  • First demyelinating event with atypical features — broaden differential (vasculitis, infection, malignancy)

Assessment

Differential diagnosis

  • Pseudorelapse (infection/fever — UTI, Uhthoff phenomenon with heat)
  • Neuromyelitis optica spectrum disorder (NMOSD) — check aquaporin-4 IgG (bilateral/severe optic neuritis, longitudinally extensive myelitis)
  • MOG antibody disease
  • First presentation: stroke, CNS vasculitis, B12 deficiency (SACD), sarcoid, Lyme, HIV, CNS lymphoma
  • Transverse myelitis / spinal cord compression
  • Functional neurological disorder
  • Migraine with aura

Investigations

  • Exclude infection: urinalysis/MSU, FBC, CRP, temperature (treat pseudorelapse by cooling/treating infection — steroids not indicated)
  • MRI brain + whole spine with gadolinium — new/enhancing lesions confirm activity (dissemination in space & time, McDonald 2017 criteria)
  • LP: oligoclonal bands (CSF-specific) support MS; cell count, protein
  • Bloods: FBC, U&E, LFT, glucose, B12, TFT, ANA, ENA, aquaporin-4 & MOG IgG, HIV, ACE (sarcoid screen)
  • Visual: VEP, OCT if optic neuritis
  • Baseline pre-DMT screen (done by neurology): JCV antibody, hepatitis B/C, VZV serology, TB screen

Management

  • Confirm genuine relapse: new objective neuro signs >24h, no fever/infection; treat any infection first (pseudorelapse improves without steroids)
  • Assess disability/function — treat relapses that are disabling (e.g. motor weakness, optic neuritis with visual loss, brainstem/cerebellar, sphincter)
  • Give corticosteroids to shorten relapse duration (does not alter long-term disability): high-dose oral or IV methylprednisolone
  • Add gastroprotection (PPI) and monitor glucose/BP/mood; caution in diabetes & infection
  • Symptomatic management: spasticity (baclofen), neuropathic pain (gabapentin/amitriptyline), fatigue, bladder dysfunction, treat UTI
  • Refer to MS specialist/neurology for DMT initiation and monitoring — DMT reduces relapse rate & disability accumulation; choose by disease activity (moderate- vs high-efficacy / early high-efficacy strategy)
  • Counsel: vaccination before immunosuppressive DMT, pregnancy planning, smoking cessation, vitamin D
  • Plavix/relapse follow-up and relapse plan

Drugs & doses

Acute relapse: methylprednisolone 500 mg-1 g PO OD for 3-5 days (oral and IV equivalent); OR IV methylprednisolone 1 g OD for 3 days [verify local dose]
Co-prescribe PPI (e.g. omeprazole 20 mg PO OD) during steroid course; monitor capillary glucose in diabetics
Severe steroid-refractory relapse (specialist): plasma exchange (PLEX)
Symptomatic spasticity: baclofen 5 mg PO TDS, titrate to effect (max ~80 mg/day); alternative tizanidine
Neuropathic pain: gabapentin 300 mg PO OD titrate, or amitriptyline 10-25 mg PO nocte
DMT (specialist-initiated, NOT ED) — moderate efficacy: dimethyl fumarate, teriflunomide, beta-interferon, glatiramer acetate
DMT high efficacy: ocrelizumab 600 mg IV every 6 months; ofatumumab 20 mg SC monthly (after loading); natalizumab; cladribine; alemtuzumab [verify local]

Disposition

Admit disabling relapse for IV steroids or if diagnostic uncertainty / severe deficit / respiratory or bulbar involvement. Mild relapse: oral steroids + urgent MS/neurology referral. All new suspected first-presentation demyelination: urgent neurology referral for confirmation and DMT decision.

Complications & pitfalls

  • Accumulating disability, secondary progressive MS
  • Optic atrophy, neurogenic bladder, spasticity, neuropathic pain, cognitive impairment, depression
  • Steroid complications: hyperglycaemia, infection, psychiatric, avascular necrosis with repeated courses
  • DMT risks: PML (natalizumab/JCV+, fingolimod), infections, infusion reactions, secondary autoimmunity (alemtuzumab)

Exam pearls

  • Always exclude infection/fever first — a pseudorelapse does not need steroids
  • Steroids shorten relapse duration but do NOT change long-term disability — only DMTs modify the disease course
  • Check aquaporin-4 & MOG IgG in severe/atypical relapses — NMOSD is treated differently (avoid some MS DMTs which can worsen it)
  • Earlier high-efficacy DMT is increasingly favoured for active disease (ECTRIMS/ABN direction) [verify local]
  • Vitamin D, smoking cessation and vaccination before immunosuppression are standard adjuncts

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.